Chardan Capital Rates Ocular Therapeutix (OCUL) buy

Chardan Capital maintains its buy rating for Ocular Therapeutix, Inc. with a price target of $23, a 133.74% upside from the current price.

By EarningsIQ Research Desk · Published Jun 25, 2026, 10:00 AM EDT · Updated Jun 29, 2026, 11:01 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Chardan Capital rated Ocular Therapeutix, Inc. ($OCUL) "buy" with a $23 price target on June 25, 2026.

Since the rating, $OCUL is down 1.2% after 1 week, down 11.5% after 1 month and down 29.6% to date (from the $9.76 close on Jun 25, 2026).

OCUL Ocular Therapeutix, Inc.

$6.87 -41.88% year to date

Daily close · Oct 16, 2026

Key Points

Chardan Capital reiterated its buy rating on Ocular Therapeutix, Inc. (OCUL) with a $23 price target on June 25, 2026.
Chardan Capital's $23 price target implies 133.74% upside from Ocular Therapeutix, Inc.'s ($OCUL) current $9.84 share price.
OCUL shares traded at $9.85 on Thursday, with a market cap of approximately $2.18 billion and no meaningful P/E ratio as it isn't profitable.
Several insiders, including CEO Dr. Pravin U. Dugel, made transactions in June, and analysts like HC Wainwright & Co. and Baird also have buy ratings.

Get $OCUL trade alerts by text

We text you when insiders, Congress or big funds trade $OCUL. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Ocular Therapeutix, Inc. alert may contain errors. Disclosures

Chardan Capital reiterated its buy rating on Ocular Therapeutix, Inc. (NasdaqGM: OCUL) on June 25, 2026, setting a price target of $23. Shares of the biopharmaceutical company traded around $9.85 on Thursday.

Other Institutional Activity in Ocular Therapeutix

FMR LLC increased its holdings by 868,159 shares, reaching a total of 32,653,764 shares valued at approximately $276.6 million. DEEP TRACK CAPITAL, LP made a significant addition of 11,615,868 shares, boosting its position by 143.9% to 19,686,282 shares worth about $166.7 million. BLACKROCK, INC. added 530,537 shares, resulting in a total of 16,132,931 shares valued at roughly $136.6 million. AVORO CAPITAL ADVISORS LLC also increased its position by 1,537,223 shares, ending with 12,315,000 shares valued at $104.3 million. Meanwhile, VENROCK ADVISER, LLC grew its stake by 3,031,379 shares, marking a 41.4% increase to 10,346,926 shares worth approximately $87.6 million.

Ocular Therapeutix, Inc. Stock Down 1.5%

Shares of Ocular Therapeutix, Inc. traded near $9.85 on Thursday. The company has a market cap of about $2.18 billion. It doesn't have a meaningful P/E ratio as it is not currently profitable, with an EPS of -$1.44. The stock has a 52-week low of $6.23 and a high of $16.44. The 50-day moving average stands at $9.02, while the 200-day moving average is $10.51. Ocular Therapeutix has a current ratio of 14.81, a quick ratio of 14.49, and a debt-to-equity ratio of 13.66.

12-month forecast

$OCUL price target

Ocular Therapeutix, Inc. daily closes and this analyst's $23 target. Not advice.

Recent Earnings

In its most recent earnings report, Ocular Therapeutix posted revenue of $52.04 million, reflecting a modest growth of 0.8%. The company reported a net margin of 0.0% and a return on equity of -68.55%. The next earnings release is anticipated on August 5, 2026.

Insider Buying and Selling at Ocular Therapeutix, Inc.

Several insiders at Ocular Therapeutix were active in June. CEO Dr. Pravin U. Dugel both sold and bought 50,092 shares on June 16. Adrienne Graves bought 44,000 shares on June 10, while Jason Shand Robins, the CFO, acquired 14,024 shares on the same day. Seung Suh Hong also purchased 14,000 shares on June 10.

Analysts Set New Price Targets

On June 25, 2026, Chardan Capital maintained its buy rating for Ocular Therapeutix with a $23 price target. HC Wainwright & Co. reiterated its buy rating on June 18 with a $25 target, while Baird maintained a buy rating with a $30 target on the same day. The consensus among analysts is a strong buy, with a mean target price of $26.91 based on 11 opinions.

About Ocular Therapeutix

Ocular Therapeutix, Inc. is a biopharmaceutical company based in Bedford, Massachusetts. It focuses on developing and commercializing therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology. The company markets DEXTENZA, a dexamethasone ophthalmic insert, and is working on other treatments like AXPAXLI and OTX-TIC for various eye diseases. Led by CEO Dr. Pravin U. Dugel, the company employs around 325 people.

Bottom Line

Chardan Capital's reiteration of a buy rating with a $23 target reflects ongoing confidence in Ocular Therapeutix's potential. Investors keep an eye on such analyses to gauge market sentiment, though it's important to remember that these ratings are based on past and current data. The company's next earnings report on August 5, 2026, will provide further insights into its financial health and future prospects.